Description |
Esculentoside A (EsA), a kind of triterpene saponin isolated from roots of Phytolacca esculenta[1].Esculentoside A (EsA) possesses anti-inflammatory activity in acute and chronic experimental models[2], has selective inhibitory activity towards cyclooxygenase-2 (COX-2)[1].Esculentoside A (EsA) suppresses inflammatory responses in LPS-induced acute lung injury (ALI) through inhibition of the nuclear factor kappa B (NF-ΚB) and mitogen activated protein kinase (MAPK) signaling pathways[3].
|
In Vitro |
Esculentoside A (0-10 μM; 24 hours) reduced the release of TNF concentration in primed macrophages [4].
|
In Vivo |
Esculentoside A (EsA) (intraperitoneal injection; 20 mg/kg; once a day; 4 weeks) plays significant roles in the treatment of BXSB mice through modulation of inflammatory cytokines, inhibition of renal cell proliferation and induction of apoptosis [2]. Esculentoside A (EsA) (injected intraperitoneally; 5, 10 and 20 mg/kg; once a day; 7 days) dose-dependently decreases the TNF, IL-1 and IL-6 levels in the sera of mice following LPS challenge[4]. Animal Model: BXSB mice[2] Dosage: 20 mg/kg Administration: Intraperitoneal injection; 20 mg/kg; once a day; 4 weeks Result: Alleviated the renal damage of LN.
|
Density | 1.4±0.1 g/cm3 |
Boiling Point | 935.8±65.0 °C at 760 mmHg |
Flash Point | 275.1±27.8 °C |
Exact Mass | 826.435059 |
PSA | 262.36000 |
LogP | 3.01 |
Vapour Pressure | 0.0±0.6 mmHg at 25°C |